Effects of once‐weekly glucagon‐like peptide‐1 receptor agonists on type 2 diabetes mellitus complicated with coronary artery disease: Potential role of the renin‐angiotensin system
Authors' conclusion
Our study suggests that once-weekly GLP-1 RA may have a potential protective effect on cardiovascular events in patients with T2DM combined with CAD, possibly through the renin-angiotensin system. However, further research is needed to confirm these findings and determine cause and effect.
Study context
- Population
- Patients with T2D complicated with coronary artery disease
- Participants
- 35,563 patients13 studies
- Comparison
- Once-weekly GLP-1 RA vs placebo or conventional treatment
- Outcome
- Non-fatal stroke
Pooled result
As reported in the abstract
- Once-weekly GLP-1 RA vs Placebo/conventional treatment: P < 0.00
Further pooled results
Cardiovascular risk factors (HbA1c, fasting blood glucose, weight, systolic BP, total cholesterol, LDL-C)
- Significantly reduced with once-weekly GLP-1 RA vs conventional treatment; HbA1c, fasting blood glucose, weight, systolic BP, total cholesterol, LDL-C each
- P < 0.00
Network pharmacology
- Key targets of dulaglutide
- 4
- Key targets of exenatide
- 5
- Key targets of semaglutide
- 2
- Enriched to the renin-angiotensin system; matrix metalloproteinase 2 and renin may be key targets
Original publication
Effects of once‐weekly glucagon‐like peptide‐1 receptor agonists on type 2 diabetes mellitus complicated with coronary artery disease: Potential role of the renin‐angiotensin system. Diabetes Obes Metab. Published 2 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →